Cognitive-behavior therapy for Japanese patients with panic disorder: Acute phase and one-year follow-up results

Psychiatry and Clinical Neurosciences

Volumn 62, Issue 3, 2008, Pages 313-321

  Nakano, Yumi ^a,c   Lee, Kiyoe ^a   Noda, Yumiko ^a   Ogawa, Sei ^a   Kinoshita, Yoshihiro ^a   Funayama, Tadashi ^a   Watanabe, Norio ^a   Chen, Junwen ^b   Noguchi, Yuka ^a   Furukawa, Toshiaki A ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Tokai Women's Junior College   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Cognitive behavioral therapy; Cross cultural; Medication; Panic disorder; Predictor

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE;

ADULT; AGORAPHOBIA; ARTICLE; COGNITIVE THERAPY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INFORMED CONSENT; INSOMNIA; INTERVIEW; JAPANESE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PANIC; PREDICTIVE VALIDITY; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL DISABILITY; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SYMPTOM CHECKLIST 90; TREATMENT DURATION; WORK CAPACITY;

ADULT; AGORAPHOBIA; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COMORBIDITY; CROSS-CULTURAL COMPARISON; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; PANIC DISORDER; PERSONALITY INVENTORY; PROGNOSIS; PSYCHOMETRICS; SOCIAL ADJUSTMENT; TREATMENT OUTCOME;

EID: 45149092913     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2008.01799.x     Document Type: Article

References (32)

1. Robins LN, Regier DA. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. The Free Press, New York, 1991.
2. Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry. 1994 51 : 8 19.
3. Ettigi P, Meyerhoff AS, Chirban JT, Jacobs RJ, Wilson RR. The quality of life and employment in panic disorder. J. Nerv. Ment. Dis. 1997 185 : 368 372.
4. Eguchi M, Noda Y, Nakano Y et al. Quality of life and social role functioning in Japanese patients with panic disorder. J. Nerv. Ment. Dis. 2005 193 : 686 689.
5. Delgado MR, Olsson A, Phelps EA. Extending animal models of fear conditioning to humans. Biol. Psychol. 2006 73 : 39 48.
6. Salkovskis PM, Clark DM, Hackman A. Treatment of panic attacks using cognitive therapy without exposure or breathing retraining. Behav. Res. Ther. 1991 29 : 161 166.
7. Marks IM, Swinson RP, Basoglu M et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br. J. Psychiatry 1993 162 : 776 787.
8. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000 83 : 2529 2536.
9. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: Systematic review. Br. J. Psychiatry 2006 188 : 305 312.
10. Martinsen EW, Olsen T, Tonset E, Nyland KE, Aarre TF. Cognitive-behavioral group therapy for panic disorder in the general clinical setting: A naturalistic study with 1-year follow-up. J. Clin. Psychiatry. 1998 59 : 437 442 quiz 443.
11. Wade WA, Treat TA, Stuart GL. Transporting an empirically supported treatment for panic disorder to a service clinic setting: A benchmarking strategy. J. Consult. Clin. Psychol. 1998 66 : 231 239.
12. Hahlweg K, Fiegenbaum W, Frank M, Schroeder B, von Witzleben I. Short- and long-term effectiveness of an empirically supported treatment for agoraphobia. J. Consult. Clin. Psychol. 2001 69 : 375 382.
13. Andrews G, Creamer M, Crino R, Hunt C, Lampe L, Page A. Panic disorder and agoraphobia. In : The Treatment of Anxiety Disordres. Clinicia's Guide and Patient Munuals, 2nd edn. Cambridge University Press, New York, 2002 36 147.
14. First MB, Spitzer RL, Gibbon M, Janet BW, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. American Psychiatric Press Inc., Washington, DC, 1997.
15. van Balkom AJ, de Beurs E, Koele P, Lange A, van Dyck R. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. J. Nerv. Ment. Dis. 1996 184 : 133 135.
16. Westra HA, Stewart SH, Conrad BE. As-needed use of benzodiazepines in managing clinical anxiety: Incidence and implications. Curr. Pharm. Des. 2002 8 : 59 74.
17. Shear MK, Brown TA, Barlow DH et al. Multicenter collaborative panic disorder severity scale. Am. J. Psychiatry 1997 154 : 1571 1575.
18. Yamamoto I, Nakano Y, Watanabe N et al. Cross-cultural evaluation of the Panic Disorder Severity Scale in Japan. Depress. Anxiety 2004 20 : 17 22.
19. Marks IM. Behavioural Psychotherapy: Maudsley Pocket Book of Clinical Management. IOP Publishing, Bristol, 1986.
20. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav. Res. Ther. 1979 17 : 263 267.
21. Chambless DL, Caputo GC, Jasinm SE, Gracely EJ, Williams C. The Mobility Inventory for Agoraphobia. Behav. Res. Ther. 1985 23 : 35 44.
22. Chambless DL, Caputo GC, Bright P, Gallagher R. Assessment of fear of fear in agoraphobics: The body sensations questionnaire and the agoraphobic cognitions questionnaire. J. Consult. Clin. Psychol. 1984 52 : 1090 1097.
23. Derogaris LR. SCL-90-R. Administration, Scoring and Procedures Manual-II for the (Revised) Version and Other Instruments of the Psychopathology Rating Scale Series. Clinical Psychometric Research Inc, Towson, MD, 1992.
24. Furukawa TA, Nakanishi M, Sakurai A, Suzuki Y, Suzuki-Moor A, Hamanaka T. Effects of ethyl loflazepate in mood and neurosis-related disorders (ICD-10 JCM); Changes in SCL-90-R subscale scores. Jpn. J. Clin. Psychiatry 1996 25 : 233 240 (in Japanese).
25. Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment Scale: A simple measure of impairment in functioning. Br. J. Psychiatry 2002 180 : 461 464.
26. Costa PT, McCrae RR. Revised NEO Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (NEO-FFI): Professional Manual. Psychological Assessment Resources, Inc, Odessa, FL, 1992.
27. Shimonaka J. Report on the Japanese Version of the NEO PI-R. Tokyo Metropolitan Institute of Gerontology, Tokyo, 1996.
28. Yoshimura K, Ono Y, Nakamura K, Nathan JH, Suzuki K. Validation of the Japanese version of the NEO Five-Factor Inventory in a large community sample. Psychol. Rep. 2001 88 : 443 449.
29. Perini SJ, Slade T, Andrews A. Generic effectiveness measures: Sensitivity to symptom change in anxiety disorders. J. Affect. Disord. 2006 90 : 123 130.
30. Basoglu M, Marks IM, Swinson RP, Noshirvani H, O'Sullivan G, Kuch K. Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. J. Affect. Disord. 1994 30 : 123 132.
31. Wardle J, Hayward P, Higgitt A, Stabl M, Blizard R, Gray J. Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia. Behav. Res. Ther. 1994 32 : 203 215.
32. Michelson LK, Marchione K. Behavioral, cognitive, and pharmacological treatments of panic disorder with agoraphobia: Critique and synthesis. J. Consult. Clin. Psychol. 1991 59 : 100 114.